Search
for
Sort by
Research 241–270 of 776
- Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial
- Baricitinib: Exploring the Safety Profile for the Treatment of Alopecia Areata
- 705 Particulate matter induces inflammatory response in human outer root sheath cells via oxidative stress-dependent MAPK and JAK-STAT signaling pathways
- Real-world evidence in alopecia areata treatment: A narrative review
- Baricitinib as a treatment for myasthenia gravis: A case report
- Diagnosis and Management of Alopecia Areata: A Saudi Expert Consensus Statement (2023)
- Alopecia areata – Current understanding and management
- Autoinmune Alopecia/Alopecia Areata
- New and Emerging Therapies for Alopecia Areata
- Alopecia areata – Aktuelles Verständnis und Management
- The Possible Role of Antibodies in Alopecia: A Narrative Review
- Alopecia Areata: Clinical Treatment
- Epigallocatechin-3 Gallate Inhibits STAT-1/JAK2/IRF-1/HLA-DR/HLA-B and Reduces CD8 MKG2D Lymphocytes of Alopecia Areata Patients
- Upadacitinib for the Management of Alopecia Totalis and Subtotalis in Pediatric Patients: A Case Series
- XMU-MP-1 induces growth arrest in a model human mini-organ and antagonises cell cycle-dependent paclitaxel cytotoxicity
- A phase 2a trial of brepocitinib for cicatricial alopecia
- Abrocitinib Improved Dupilumab-Resistant Severe Atopic Dermatitis with Comorbid Mild Alopecia Areata in a 12-Year-Old Boy: A Case Report with 1-Year Follow-Up
- Case report: Psoriasiform eczema with immune-mediated comorbidities treated with upadacitinib
- Oclacitinib Treatment and Surgical Management in a Case of Periocular Eosinophilic Furunculosis and Vasculitis with Secondary Eyelid Fusion in a Diabetic Cat
- Advancements in Bioactive Compounds and Therapeutic Agents for Alopecia: Trends and Future Perspectives
- Deciphering the Complex Immunopathogenesis of Alopecia Areata
- Ruxolitinib protects skin stem cells and maintains skin homeostasis in murine graft-versus-host disease
- The Role of Janus Kinase Inhibitors in Dermatology
- P718 Observational real-world evidence on the efficacy and safety of Janus Kinase inhibitors (JAKi) in the treatment of moderate to severe Active Ulcerative Colitis (UC)
- Various Applications of Tofacitinib and Ruxolitinib (Janus Kinase Inhibitors) in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective
- JAK-inhibitors in the therapy of comorbid diseases – atopic dermatitis and alopecia areata: literature review and experience of clinical practice
- The Role of JAK Inhibitors in Atopic Dermatitis, Alopecia Areata, and Vitiligo: A Review article
- Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata
- 277 An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata
- Recalcitrant alopecia areata responsive to leflunomide and anthralin—Potentially undiscovered JAK/STAT inhibitors?